Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Daewoong, first runner for generic Cymbalta
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Oct 10, 2012 10:20:45
The Korea Food and Drug Administration (KFDA) approved Daewoong’s bioequivalence testing protocol for the generic version of Cymbalta.

The post-marketing surveillance study for Cymbalta won’t be required any longer in July, 2012. Daewoong seems to plan its generic version of Cymbalta, considering the overall timeline.

Lilly Korea got its marketing approval for Cymbalta in 2007. Cymbalta sales were 7 billion won last year. It took three years for Cymbalta to be listed on the nation’s drug formulary as the price negotiation didn’t end on time.

Daewoong is the first company who tries generic Cymbalta. More companies will enter the market soon.
Reply 0
Name Password
Popular News
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com